{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:16:53Z","timestamp":1778087813216,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.yrtph.2026.106098","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:00:20Z","timestamp":1776142820000},"page":"106098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advancing nonclinical blood pressure assessment: Current practices and future directions in drug development"],"prefix":"10.1016","volume":"169","author":[{"given":"Michael K.","family":"Pugsley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Gottfridsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yevgeniya E.","family":"Koshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-0681","authenticated-orcid":false,"given":"Jennifer","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric I.","family":"Rossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Taraboletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja S.","family":"Zabka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106098_bib1","series-title":"SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A","year":"2000"},{"key":"10.1016\/j.yrtph.2026.106098_bib2","series-title":"Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry","year":"2022"},{"issue":"21","key":"10.1016\/j.yrtph.2026.106098_bib3","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2026.106098_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vascn.2015.03.003","article-title":"A non-human primate model for investigating drug-induced risk of orthostatic hypotension and sympathetic dysfunction: preclinical correlate to a clinical test","volume":"73","author":"Bhatt","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106098_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.vascn.2016.04.003","article-title":"Statistical power analysis of cardiovascular safety pharmacology studies in conscious rats","volume":"81","author":"Bhatt","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106098_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/toxsci\/kfz035","article-title":"Preclinical to clinical translation of hemodynamic effects in cardiovascular safety pharmacology studies","volume":"169","author":"Bhatt","year":"2019","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106098_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicol. Sci."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106098_bib8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106098_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cpt.1690","article-title":"Redefining blood pressure assessment - the role of the ambulatory blood pressure monitoring study for drug safety","volume":"107","author":"Garnett","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106098_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.vascn.2005.11.004","article-title":"Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving laboratory beagle dog by remote radiotelemetry","volume":"53","author":"Gauvin","year":"2006","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2026.106098_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2025.108385","article-title":"A retrospective analysis of the concordance between cardiovascular effects in telemetry studies, toxicity studies, and early clinical trials","volume":"135","author":"Greiter-Wilke","year":"2025","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"22","key":"10.1016\/j.yrtph.2026.106098_bib12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2026.106098_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.vascn.2015.02.002","article-title":"The evaluation of drug-induced changes in cardiac inotropy in dogs: results from a HESI-sponsored consortium","volume":"75","author":"Guth","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106098_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1573402115666190301144316","article-title":"The adaptive value and clinical significance of allostatic blood pressure variation","volume":"15","author":"James","year":"2019","journal-title":"Curr. Hypertens. Rev."},{"key":"10.1016\/j.yrtph.2026.106098_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107109","article-title":"Automated blood sampling in canine telemetry studies: enabling enhanced assessments of cardiovascular liabilities and safety margins","volume":"111","author":"Koshman","year":"2021","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"9349","key":"10.1016\/j.yrtph.2026.106098_bib16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"8692","key":"10.1016\/j.yrtph.2026.106098_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias","volume":"335","author":"MacMahon","year":"1990","journal-title":"Lancet"},{"issue":"44","key":"10.1016\/j.yrtph.2026.106098_bib18","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/eurheartj\/ehx508","volume":"38","author":"Ruschitzka","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106098_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vascn.2010.05.011","article-title":"Cardiovascular safety assessments in the conscious telemetered dog: utilisation of super-intervals to enhance statistical power","volume":"62","author":"Sivarajah","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:56:15Z","timestamp":1778086575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S0273230026000711"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106098","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing nonclinical blood pressure assessment: Current practices and future directions in drug development","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106098"}}